Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature

Pediatric Drugs

Volumn 19, Issue 1, 2017, Pages 21-34

  Donnelly, Patrick C ^a,b   Sutich, Rebecca M ^a,b   Easton, Ryan ^a   Adejumo, Oluwatunmise A ^a   Lee, Todd A ^a   Logan, Latania K ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b American Academy of Orthopaedic Surgeons   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CEFTRIAXONE; ANTIINFECTIVE AGENT;

ANOREXIA; BILIRUBIN BLOOD LEVEL; CARDIOPULMONARY INSUFFICIENCY; DATA BASE; DIARRHEA; DRUG SAFETY; DRUG SCREENING; FEVER; GROUP B STREPTOCOCCAL INFECTION; HUMAN; HYPERALIMENTATION; HYPERBILIRUBINEMIA; INFECTION; INJECTION SITE REACTION; LETHARGY; MENINGITIS; NEWBORN; OUTCOME ASSESSMENT; PERINATAL ASPHYXIA; PERSISTENT PULMONARY HYPERTENSION; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; PSEUDOLITHIASIS; PULMONARY HYPERTENSION; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SEPSIS; STONE FORMATION; SYSTEMATIC REVIEW; THROMBOCYTOSIS; TREATMENT INDICATION; URINARY TRACT INFECTION; VOMITING; BLOOD; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; BILIRUBIN; CEFTRIAXONE; HUMANS; INFANT, NEWBORN;

EID: 84990976048     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-016-0197-x     Document Type: Review

References (34)

1. Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Drugs. 1995;50(3):423–39.
2. Katzung B, Trevor A. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill; 2014.
3. Monte SV, Prescott WA, Johnson KK, Kuhman L, Paladino JA. Safety of ceftriaxone sodium at extremes of age. Expert Opin Drug Saf. 2008;7(5):515–23.
4. US Food and Drug Administration. Information for healthcare professionals: ceftriaxone (marketed as Rocephin). 2007. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm134328.htm. Accessed 20 Apr 2016.
5. US Food and Drug Administration. Information for healthcare professionals: ceftriaxone (marketed as Rocephin). 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm. Accessed 20 Apr 2016.
6. Gulian JM, Dalmasso C, Pontier F, Gonard V. Displacement effect of ceftriaxone on bilirubin bound to human serum albumin. Chemotherapy. 1986;32(5):399–403.
7. Fink S, Karp W, Robertson A. Ceftriaxone effect on bilirubin-albumin binding. Pediatrics. 1987;80(6):873–5.
8. Brodersen R, Robertson A. Ceftriaxone binding to human serum albumin: competition with bilirubin. Mol Pharmacol. 1989;36(3):478–83.
9. Martin E, Fanconi S, Kalin P, Zwingelstein C, Crevoisier C, Ruch W, et al. Ceftriaxone–bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr. 1993;152(6):530–4.
10. Gulian JM, Gonard V, Dalmasso C, Palix C. Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of ‘free’ bilirubin and erythrocyte-bound bilirubin. J Antimicrob Chemother. 1987;19(6):823–9.
11. Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis. 1986;5(6):708–10.
12. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium–ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100(6):1665–70.
13. Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium–ceftriaxone binding and solubility. Gastroenterology. 1990;99(6):1772–8.
14. Famularo G, Polchi S, De SC. Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication. Ann Ital Med Int. 1999;14(3):202–4.
15. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427–37.
16. McCarthy CA, Powell KR, Jaskiewicz JA, Carbrey CL, Hylton JW, Monroe DJ, et al. Outpatient management of selected infants younger than two months of age evaluated for possible sepsis. Pediatr Infect Dis J. 1990;9(6):385–9.
17. Bradley JS, Ching DL, Wilson TA, Compogiannis LS. Once-daily ceftriaxone to complete therapy of uncomplicated group B streptococcal infection in neonates. A preliminary report. Clin Pediatr (Phila). 1992;31(5):274–8.
18. Wagner CL, Wagstaff P, Cox TH, Annibale DJ. Early discharge with home antibiotic therapy in the treatment of neonatal infection. J Perinatol. 2000;20(6):346–50.
19. Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609–13.
20. Van Reempts P, Van Overmeire B, Mahieu LM, Vanacker KJ. Clinical experience with ceftriaxone treatment in the neonate. Chemotherapy. 1995;41(4):316–22.
21. Takei T, Chiba N, Fujita H, Morozumi M, Kuwata Y, Kishii K, et al. Late-onset invasive group B streptococcal infection with serotype VIII in a neonate having congenital biliary atresia. Pediatr Neonatol. 2013;54(1):63–6.
22. James J, Mulhall A, de Louvois J. Ceftriaxone: clinical experience in the treatment of neonates. J Infect. 1985;11(1):25–33.
23. Martin E. Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children. Eur J Clin Microbiol. 1983;2(5):509–15.
24. American Liver Foundation. Biliary atresia. 2015. http://www.liverfoundation.org/abouttheliver/info/biliaryatresia/. Accessed 1 Apr 2016.
25. Pacifici GM. Pharmacokinetics of cephalosporins in the neonate: a review. Clinics (Sao Paulo). 2011;66(7):1267–74.
26. Long SS, Pickering LK, Prober CG. Principles and practice of pediatric infectious diseases. 4th ed. Philadelphia: Churchill Livingstone/Elsevier; 2012.
27. Coppini R, Simons SH, Mugelli A, Allegaert K. Clinical research in neonates and infants: challenges and perspectives. Pharmacol Res. 2016;108:80–7.
28. Sheu JC, Chang PY, Chen CC, Lee HC, Huang FY. Surgical management of complicated gastrointestinal salmonellosis in children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1993;34(2):84–90.
29. Oli K, Haimanot RT, Gedebou M, Tsega E. Ceftriaxone in the treatment of septicaemia due to multiple drug resistant bacteria. Cent Afr J Med. 1990;36(3):68–71.
30. Adeboye MA, Obasa TO, Fadeyi A, Adesiyun OO, Mokuolu OA. Haemophilus meningitis in an African neonate: time for active surveillance and institution of appropriate control measure. West Afr J Med. 2010;29(4):275–7.
31. Etzel RA. What the primary care pediatrician should know about syndromes associated with exposures to mycotoxins. Curr Probl Pediatr Adolesc Health Care. 2006;36(8):282–305.
32. Darville T, Jacobs RF. The role of third generation cephalosporins in serious pediatric infections. Complicat Surg. 1995;14(1):73–8.
33. Matthess A, Isenberg H, Gulian JM, Dalamasso C, Ruch W, Martin E, et al. Elucidating relevance of bilirubin-displacing effect of ceftriaxone in neonatal sepsis by determination of unbound ‘free’ bilirubin. Pediatr Relat Topics. 1996;35(4):341–53.
34. Vandenbroucke JP, Von EE, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805–35.